Literature DB >> 11961730

[Cost measurement based on a cost diary in patients with inflammatory bowel disease].

M Rösch1, R Leidl, C von Tirpitz, M Reinshagen, G Adler, H H König.   

Abstract

OBJECTIVE: Cost diaries administered by patients have been used as a method to measure costs for different diseases. Our aim was to test the application of a patient cost diary in patients with inflammatory bowel disease (IBD) and to measure disease specific resource utilization and costs. PATIENTS AND METHODS: A specific patient cost diary for IBD was developed and tested in a prospective pilot study. 105 outpatients with IBD of a University Hospital agreed to participate over a 4 week follow-up period. They were asked to report weekly their use of medical care and costs related to their illness. Visits to health care providers, hospitalizations, drug use, costs due to absence from paid and unpaid work, travel costs as well as out-of-pocket expenses were considered.
RESULTS: The response rate was 90 %. Almost 70 % of the patients estimated the diary as easy to fill in. Compared with other data sources, the cost measurement using the cost diary showed good agreement regarding costs of drug therapy and outpatient hospital treatment. Mean costs due to illness were estimated to be 1,500 Euro per 4 weeks. This corresponds to total costs of about 20,000 Euro per year of care. 69 % of total costs were indirect costs due to illness-related absence from work, days of inactivity at home, and early retirement. Direct health care and direct non health care costs (e. g. travel costs) were responsible for 27 % and 4 % of costs, respectively. DISCUSSION AND
CONCLUSION: The presented instrument offers a suitable and practical method of assessing IBD-related resource utilization. The prospectively obtained data for direct medical and non medical, as well as indirect costs allow a cost measurement from the societal perspective. The presented cost diary can be used for measuring costs for economic evaluations of medical interventions.

Entities:  

Mesh:

Year:  2002        PMID: 11961730     DOI: 10.1055/s-2002-25153

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  9 in total

1.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Health care costs and their predictors of inflammatory bowel diseases in Germany.

Authors:  Anne Prenzler; Bernd Bokemeyer; J-Matthias von der Schulenburg; Thomas Mittendorf
Journal:  Eur J Health Econ       Date:  2010-10-22

3.  [Chronic inflammatory bowel diseases competence network ].

Authors:  U R Fölsch; J Grebe; S Schreiber
Journal:  Internist (Berl)       Date:  2004-04       Impact factor: 0.743

4.  Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

Authors:  A Bassi; S Dodd; P Williamson; K Bodger
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

5.  [Clinical practice guideline on diagnosis and treatment of Crohn's disease - summary for the general practitioner].

Authors:  Jan C Preiss; Bernd Bokemeyer; Britta Siegmund; Eduard F Stange; Martin Zeitz; Jörg C Hoffmann
Journal:  Med Klin (Munich)       Date:  2009-03-15

6.  Health-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis.

Authors:  W Hens; D Vissers; L Annemans; J Gielen; L Van Gaal; J Taeymans; N Verhaeghe
Journal:  Arch Public Health       Date:  2018-07-30

7.  How to collect non-medical data in a pediatric trial: diaries or interviews.

Authors:  Anaïs Le Jeannic; Hassani Maoulida; Sophie Guilmin-Crépon; Corinne Alberti; Nadia Tubiana-Rufi; Isabelle Durand-Zaleski
Journal:  Trials       Date:  2020-01-07       Impact factor: 2.279

8.  Psychiatric comorbidity as predictor of costs in back pain patients undergoing disc surgery: a longitudinal observational study.

Authors:  Alexander Konnopka; Margrit Löbner; Melanie Luppa; Dirk Heider; Sven Heinrich; Steffi Riedel-Heller; Hans Jörg Meisel; Lutz Günther; Jürgen Meixensberger; Hans-Helmut König
Journal:  BMC Musculoskelet Disord       Date:  2012-09-03       Impact factor: 2.362

9.  Growing old at home - a randomized controlled trial to investigate the effectiveness and cost-effectiveness of preventive home visits to reduce nursing home admissions: study protocol [NCT00644826].

Authors:  Steffen Fleischer; Gudrun Roling; Katrin Beutner; Stephanie Hanns; Johann Behrens; Tobias Luck; Bettina Kuske; Matthias C Angermeyer; Steffi G Riedel-Heller; Sven Heinrich; Hans-H König; Christine Lautenschläger
Journal:  BMC Public Health       Date:  2008-05-28       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.